SCHEMBL12414217

SCHEMBL12414217

CC(CCN1C(=O)C=CC1=O)N1C(=O)C=CC1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 10/20 0.48
FAAH O00519 4/20 0.48
ALDH1A1 P00352 2/20 0.46
LMNA P02545 2/20 0.46
MAPT P10636 2/20 0.46
NPSR1 Q6W5P4 2/20 0.46
HSP90AA1 P07900 2/20 0.46
TLR9 Q9NR96 1/20 0.46
TP53 P04637 1/20 0.46
PKM P14618 1/20 0.46
HPGD P15428 1/20 0.46
XBP1 P17861 1/20 0.46
MAPK1 P28482 1/20 0.46
HTT P42858 1/20 0.46
RECQL P46063 1/20 0.46
RAB9A P51151 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
GPR35 Q9HC97 1/20 0.46
GPR55 Q9Y2T6 1/20 0.46
PTGS1 P23219 7/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20072963 0.88 MGLL (0.56) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL3623634 0.86 MGLL (0.59) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL18372942 0.85 MGLL (0.61) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL28871457 0.85 MGLL (0.61) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL3482800 0.80 MGLL (0.54) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL11128738 0.78 MGLL (0.52) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL1535503 0.78 GAA (0.42) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL8168349 0.78 MGLL (0.46) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL4418973 0.77 GABBR2 (0.35) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL22544689 0.77 MGLL (0.50) MGLLFAAHALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9493609-B2 N-maleimidyl polymer derivatives NEKTAR THERAPEUTICS (US) 2016-11-15 US disclosed
US-20160083514-A1 N-MALEIMIDYL POLYMER DERIVATIVES NEKTAR THERAPEUTICS 2016-03-24 US disclosed
US-9169350-B2 N-maleimidyl polymer derivatives NEKTAR THERAPEUTICS (US) 2015-10-27 US disclosed
US-20150166725-A1 N-Maleimidyl Polymer Derivatives NEKTAR THERAPEUTICS (US) 2015-06-18 US disclosed
US-8992902-B2 N-maleimidyl polymer derivatives NEKTAR THERAPEUTICS (US) 2015-03-31 US disclosed
US-20140256957-A1 N-Maleimidyl Polymer Derivatives NEKTAR THERAPEUTICS (US) 2014-09-11 US disclosed
US-20110166063-A1 POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES NEKTAR THERAPEUTICS (US) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166063-A1 POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES NGLY1, CD44, IAPP MGLL 4175/4885FAAH 4134/4885ALDH1A1 3923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.